Mostly broad re-summary. Good to use to get some people up to speed quickly.
personally i was unaware of Momenta
"But companies such as Cambridge, Massachusetts–based Momenta, which specializes in characterization, say they have the expertise to identify any differences between a biogeneric and its reference product, and that these data can be used to direct further development and review of the drug. “What we’re doing is what Congress says can’t be done,” says Craig Wheeler, CEO of Momenta."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.